
|Articles|March 3, 2022
Daily Medication Pearl: Rocuronium Bromide
Author(s)Saro Arakelians, PharmD
Rocuronium bromide is indicated as an adjunct to general anesthesia and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Advertisement
Indication: Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Insight:
- Dosing: Individualize the dose for each patient.
- Dosage forms: 5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL), 10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL).
- Adverse events: Most common adverse reactions (2%) are transient hypotension and hypertension.
- Mechanism of action: Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor endplate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
- Manufacturer: Teva Pharmaceuticals
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
2
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































